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Glutathione peroxidase 3 (GPx3) accounts for the
major antioxidant activity in the plasma. Here, we
demonstrate that down-regulation of GPx3 in the
plasma of obese subjects is associated with adi-
pose GPx3 dysregulation, resulting from the in-
crease of inflammatory signals and oxidative
stress. Although GPx3 was abundantly expressed
in kidney, lung, and adipose tissue, we observed
that GPx3 expression was reduced selectively in
the adipose tissue of several obese animal models
as decreasing plasma GPx3 level. Adipose GPx3
expression was greatly suppressed by prooxida-
tive conditions such as high levels of TNF and
hypoxia. In contrast, the antioxidant N-acetyl cys-
teine and the antidiabetic drug rosiglitazone in-
creased adipose GPx3 expression in obese and
diabetic db/db mice. Moreover, GPx3 overexpres-
sion in adipocytes improved high glucose-induced
insulin resistance and attenuated inflammatory gene
expression whereas GPx3 neutralization in adipo-
cytes promoted expression of proinflammatory
genes. Taken together, these data suggest that sup-
pression of GPx3 expression in the adipose tissue of
obese subjects might constitute a vicious cycle to
expand local reactive oxygen species accumulation
in adipose tissue potentially into systemic oxidative
stress and obesity-related metabolic complications.
(Molecular Endocrinology 22: 2176–2189, 2008)
ADIPOSE TISSUE contributes to maintaining theenergy homeostasis of the whole body not only by
buffering lipid metabolites but also by secreting sev-
eral adipocytokines in response to the inputs of the
central nervous system and periphery (1). In obesity,
however, adipose tissue fails to accommodate fatty
acids effectively according to the changing metabolic
requirements, resulting in excessive accumulation of
lipid metabolites in peripheral tissues, including the
liver and muscle tissues, along with adipocytokine
dysregulation (2). The abnormal regulation of adipocy-
tokines occurring in obesity affects the functions of
other tissues, including the liver, muscle, central ner-
vous system, and vasculatures, thus increasing the
risks for metabolic complications. Therefore, it ap-
pears that examining the molecular regulatory mech-
anisms for adipocytokines in obesity is crucial for un-
derstanding metabolic disorders and for developing
effective therapeutic interventions for obesity and its
related complications.
One of the main clinical manifestations of obesity is
increased systemic oxidative stress (3–5). Oxidative
stress has been implicated in several forms of tissue
damage and leads to pathological conditions such as
irradiation damage and ischemia reperfusion injury, as
well as neurodegenerative diseases (6, 7). However,
accumulating evidence indicates that increased oxi-
dative stress is also strongly associated with meta-
bolic disorders, including atherosclerosis, thrombosis,
liver steatosis, and diabetes mellitus, which are often
observed in morbid obesity (8–11). Reactive oxygen
species (ROS) can rapidly inactivate vascular nitrogen
oxide (NO), a major vasorelaxant and inhibitor of plate-
let function, and can increase the risks for atheroscle-
rosis and stroke. Moreover, posttranslational modifi-
cations of fibrinogen by ROS and NO-derived oxidants
enhance fibrinogen activity, thus accelerating clot for-
mation and thrombosis (12, 13). In addition, oxidative
stress impairs insulin secretion by the pancreatic
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-cells (14) as well as glucose transport into the mus-
cle (15) and adipose tissue (16).
Recently, it has been shown that ROS generation is
selectively increased in the fat tissues of obese mice,
resulting in insulin resistance and dysregulation of adi-
pocytokine gene expression (5). Interestingly, several
insulin resistance-inducing factors such as TNF and
dexamethasone, as well as free fatty acids and high
glucose levels, potently stimulate ROS production in
adipocytes (5, 17, 18). On the other hand, antioxidant
molecules such as N-acetyl cysteine (NAC), manga-
nese (III) tetrakis (4-benzoic acid) porphyrin, and apo-
cynin not only reverse TNF-induced dysregulation of
adipocytokine gene expression but also ameliorate
insulin resistance, hyperlipidemia, and liver steato-
sis in obese animals, without altering the body
weight (5, 17). Thus, it appears that increased sys-
temic oxidative stress stemming from the expansion
of adipose tissue during developing obesity may
play a role in mediating obesity-related metabolic
complications.
The cellular redox potential is maintained by a bal-
anced regulation of prooxidative and antioxidative en-
zymes. The catalytic triad of superoxide dismutase,
catalase (CAT), and glutathione peroxidase (GPx) is an
antioxidant system for removing superoxide anions
and is well conserved from prokaryotes to eukaryotes
(12). Superoxide dismutase converts superoxide an-
ions to H2O2, which is further catalyzed by GPx and
CAT into a harmless product, H2O. CAT recognizes
only H2O2 as its substrate and functions with very low
affinity (19). Thus, it mainly functions only at H2O2
levels above the physiological level; these conditions
may arise during oxidative burst in response to stress.
On the other hand, GPx metabolizes peroxidized or-
ganic molecules as well as H2O2, recycles some of the
molecules attacked by H2O2 with a relatively high af-
finity, and catalyzes these molecules even at the nor-
mal physiological concentrations (20). Therefore, GPx
activity is considered to represent the initial protective
response required for adjusting the H2O2 concentra-
tion under normal physiological conditions as well as
after oxidative insult.
To date, seven isoforms of GPx proteins have been
identified in mice (21). Of these, only GPx3 is found in
the plasma and accounts for a major part of the
plasma GPx activity (21). A large amount of GPx3 is
synthesized in and secreted from the kidneys and
lungs; it maintains the bioavailability of vascular NO
and scavenges H2O2 and peroxidized organic mole-
cules in the plasma to reduce systemic oxidative
stress (22, 23).
In this study, we demonstrated that GPx3 was highly
expressed in the adipose tissue, and its expression
was reduced in both sera and fat tissues of obese
subjects. Because GPx3 was reduced selectively in
the fat tissues of obese mice, we propose that ele-
vated systemic oxidative stress in obesity is associ-
ated with reduced circulating GPx3 expression, prob-
ably by diminished adipose GPx3 expression.
RESULTS
Systemic Oxidative Stress in Obesity Is
Associated with Reduced Circulating
GPx3 Expression
Recently, it has been reported that a systemic increase
in oxidative stress is often observed in obese subjects
and is regarded to be directly involved in increasing
incidence of obesity-related metabolic complications
including diabetes mellitus and cardiovascular dis-
eases (3–5). Consistent with these reports, we ob-
served that obese and diabetic db/db mice exhibited
increased plasma ROS and oxidative damages, which
were assessed in terms of thiobarbituric acid-reactive
substances (TBARS) concentration (Fig. 1, A and B).
While analyzing protein expression profile in the
plasma of normal and obese mice, we found that the
circulating GPx3 level was greatly decreased in the
obese subjects (Fig. 1C). Concurrently, we observed
that the total GPx activity in the plasma was reduced
in the obese mice (Fig. 1D). Similar to the data ob-
tained from the obese animal models, the plasma lev-
els of the GPx3 protein and the total plasma GPx
activity were substantially diminished even in obese
human subjects (Fig. 1, E and F). These results sug-
gest that increased oxidative stress in obesity appears
to be linked with reduced circulating GPx3 expression.
GPx3 Is Abundantly Expressed in Adipose Tissue
as Well as Kidney and Lung
To examine tissue distribution of the GPx3, we per-
formed Northern blot analyses with mouse tissues.
Previously, it has been shown that GPx3 is abundantly
expressed in kidney, lung, and fat tissue in humans
(24). Consistently, we observed that GPx3 mRNA
was highly expressed in the kidney, lung, and white
adipose tissue (WAT) of B6 mice (Fig. 2A). Moreover,
GPx3 was highly expressed in brown adipose tissue
(BAT) (Fig. 2A). In addition, GPx3 expression in the
WAT was remarkably reduced in diet-induced obese
mice than in the control mice (Fig. 2A).
Next, we determined relative expression of GPx3 in
adipocytes and stromal vascular cells (SVCs) isolated
from the adipose tissue. Recently, it was reported that
GPx3 is induced during adipogenesis of human and
bovine preadipocytes (25, 26). In accordance with this
report, GPx3 was more abundantly expressed in adipo-
cytes than in SVCs of B6 mouse adipose tissue (Fig. 2B).
Moreover, its mRNA expression was elevated during
adipocyte differentiation of 3T3-L1 (Fig. 2C). We also
examined the expression of adiponection mRNA as a
control for adipocyte marker gene (27). However, the
GPx3 mRNA level was considerably lower (250-fold
less) in the 3T3-L1 adipocytes than in the mouse
primary adipocytes, as frequently observed in other
cell lines derived from the tissues abundantly ex-
pressing GPx3 (28).
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GPx3 Expression Is Reduced in the Adipose
Tissue, But Not Kidney, of Obese Mice
Because GPx3 mRNA was expressed most abun-
dantly in kidney, we decided to determine whether the
diminished circulating GPx3 level in obese subjects is
associated with GPx3 expression in the kidneys. When
we analyzed GPx3 expression, both mRNA and pro-
tein levels of GPx3 were not altered or even slightly
increased in the kidneys of ob/ob and db/db obese
mice (Fig. 3A) (see supplemental Figs. 1 and 2 pub-
lished as supplemental data on The Endocrine Society’s
Journals Online web site at http://mend.endojournals.
org data). In contrast, GPx3 mRNA was significantly re-
duced in the WAT of obese animal models including
ob/ob and db/db mice, as compared with that in lean
mice (Fig. 3B); this result is consistent with the previous
report that GPx3 is suppressed in the adipose tissue of
obese fatty OLETF rats (29). Further, a similar reduction
in the GPx3 expression was selectively observed in sev-
eral adipose tissues of obese mice (supplemental Fig. 2).
Furthermore, reduced GPx3 expression was mainly ob-
served in the adipocytes but not in the SVCs isolated
from the WAT of db/db mice (Fig. 3C) (supplemental Fig.
3). Notably, TNF was induced in the WAT of ob/ob and
db/db mice (Fig. 3B) as expected (30). Moreover, the
GPx3 protein level and total GPx activity in the WAT of
obese ob/ob and db/db mice were significantly dimin-
ished (Fig. 3, D and E). Concurrent with these findings,
the levels of total ROS and TBARS found to be elevated
in the WAT of db/db mice (Fig. 3, F and G). Together, it
is likely that reduced plasma GPx3 levels observed in
obese subjects is presumably due to reduced GPx3
expression in the fat tissues rather than in the kidneys
(Figs. 1–3).
Adipose GPx3 Expression Is Suppressed by
TNF, Lipopolysaccharide (LPS), and Hypoxia,
Whereas It Is Stimulated by the Antioxidant NAC
It is well established that obesity is closely associated
with ROS accumulation and with increased proinflam-
matory gene expression in adipose tissue (5, 30).
Functioning as a key proinflammatory cytokine, TNF
expression is elevated in the fat tissues of obese mice,
and it stimulates the expression of prooxidative genes
Fig. 1. Systemic Increase in Oxidative Stress in Obese Subjects Is Associated with Decreasing Circulating GPx3 Expression
A, ROS concentration in the serum samples obtained from lean and obese db/db mice. B, Systemic oxidative damage as
reflected by the TBARS concentrations in the serum samples from lean and obese db/db mice. The values represent the means 
SEM (n  4 or 8). C, Western blot analyses of GPx3 protein expression in the serum samples of lean, ob/ob, and db/db mice. D,
GPx activity assays on the serum samples from lean and obese mice. E and F, GPx3 protein expression (E) and GPx activity (F)
are reduced in the serum of obese human subjects. Lean, body mass index 25; obese, body mass index 30. Error bars indicate
the SEM (n  3 or 4). *, P  0.05; **, P  0.01. AdipoQ, Adiponectin.
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such as inducible nitric oxide synthase (iNOS) and nico-
tinamide adenine dinucleotide phosphate (NADPH) oxi-
dase (30). To determine whether this augmented expres-
sion of TNF is related to the reduced adipose GPx3
expression observed in obese mice, we treated
3T3-L1 adipocytes as well as mouse epididymal fat
tissue with TNF and analyzed their GPx3 mRNA ex-
pression. As previously reported (31, 32), TNF in-
duced inflammatory genes, including TNF, SAA3,
and iNOS, whereas it decreased the peroxisomal pro-
liferator-activated receptor (PPAR) and adiponectin
mRNA levels (Fig. 4, A and B). Interestingly, TNF
significantly decreased the GPx3 expression in both
3T3-L1 adipocytes and epididymal fat tissue (Fig. 4, A
and B; and see supplemental Fig. 4).
To directly ascertain whether inflammatory signals
affect the adipose GPx3 expression in vivo, lean mice
were treated with LPS, and the GPx3 mRNA expres-
sion levels and total GPx activities in fat tissues were
measured. As shown in Fig. 4, C and D, both GPx3
expression and GPx activity were repressed in the
adipose tissue by LPS-induced systemic inflamma-
tion, whereas the level of kidney GPx3 mRNA was
enhanced by LPS (Fig. 4E). These results imply that
increased inflammatory signals present in obesity could
selectively down-regulate adipose GPx3 expression.
Hypoxic conditions stimulate ROS generation in
several cell types and induce inflammatory gene ex-
pression (33). Recent reports have demonstrated the
adipose tissue of obese mice to be hypoxic (34, 35),
and hypoxia interferes with adipocyte differentiation
as well as adipocytokine expression (36–38). To ex-
amine the effects of hypoxia on adipose GPx3 expres-
sion, 3T3-L1 adipocytes were treated with CoCl2, a
well-known hypoxia mimetic (37, 39–41). As expected,
treatment of CoCl2 reduced the expression of PPAR
and adiponectin, whereas it stimulated vascular endo-
thelial growth factor expression (36) (Fig. 4F). Simul-
taneously, CoCl2 markedly suppressed GPx3 expres-
sion (Fig. 4F); this implies that hypoxia might also be a
possible factor for the reduced adipose GPx3 expres-
sion observed in obese animals.
To clarify whether the decreased adipose GPx3 ex-
pression occurring in obesity may be due to oxidative
stress with chronic inflammation and/or hypoxia, we
administered a potent antioxidant chemical, NAC, to
obese db/db mice, and we examined the GPx3 ex-
pression in the fat tissues. In accordance with the in
vitro and in vivo data described above, NAC treatment
enhanced GPx3 expression but reduced iNOS expres-
sion in the fat tissues of db/db mice (Fig. 4G). In
contrast, GPx3 expression in the kidneys was reduced
by NAC treatment in db/db mice (Fig. 4H), implying
that GPx3 may be regulated by distinct mechanisms in
adipose tissue and kidney in response to oxidative
stress. Taken together, these in vitro, ex vivo, and in
vivo data suggest that the reduced adipose GPx3
expression observed in obese mice would be tightly
regulated by oxidative insults as well as inflammatory
signals in an adipose tissue-specific manner.
Rosiglitazone and PPAR Stimulate
GPx3 Expression
Functioning as a master transcription factor for adipo-
genesis, PPAR is involved in regulating the expression
of several adipocytokine genes, including leptin, resistin,
and adiponectin (42). PPAR activation by its ligand
thiazolidinediones (TZDs) improves insulin sensitivity
and protects cells from oxidative stress-induced apo-
ptosis (43–47). Because GPx3 was abundantly ex-
pressed in the WAT and BAT, we investigated the
effects of PPAR activation on adipose GPx3 expres-
sion. After treating 3T3-L1 adipocytes with rosiglita-
zone, the GPx3 mRNA level was dramatically elevated
(Fig. 5A). Moreover, the administration of rosiglitazone
Fig. 2. GPx3 Is Abundantly Expressed in Adipose Tissue
A, Total RNA was isolated from several tissues of lean C57BL6 mice and was subjected to Northern blot analyses. DIO,
Diet-induced obese. B, GPx3 mRNA expression in the two fractions—SVCs and adipocytes (Adipo)—obtained by collagenase
digestion of WAT. Total RNA isolated from each fraction was analyzed by quantitative real-time RT-PCR. Adiponectin (AdipoQ)
was used as a maker gene of adipocytes. C, GPx3 mRNA expression in the preadipocytes (Pre) and adipocytes (Adipo) of 3T3-L1
was analyzed by quantitative real-time RT-PCR. Error bars indicate the SEM (n  3).
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to db/db mice restored the GPx3 expression in the fat
tissues up to the level observed in lean mice (Fig. 5B)
and abated oxidative stress, as reflected by the
TBARS levels (Fig. 5C). However, GPx3 expression in
kidney was not altered by rosiglitazone treatment
(supplemental Fig. 5). To assess whether PPAR is
involved in the expression of adipose GPx3, we ana-
lyzed the mouse GPx3 promoter and found, at least,
three putative PPAR response element (PPRE) motifs
localized approximately at 1.4 kb (PPRE1), 2.4 kb
(PPRE2), and 3.1 kb (PPRE3) away from the tran-
scription start site (Fig. 5D). Next, we performed gel
shift assays with ARE7 containing an endogenous
PPRE from aP2 gene (48). As shown in Fig. 5E, all the
three putative PPRE motifs from mouse GPx3 pro-
moter competed with ARE7 probe, suggesting that the
three PPREs might be potential binding sites for
PPAR/retinoid X receptor (RXR) in vitro. For further
analysis of the PPREs in mouse GPx3 promoter,
PPAR binding activity was determined with chroma-
tin immunoprecipitation (ChIP) assays in adipocytes.
As shown in Fig. 5F, substantial binding of PPAR was
detected only around PPRE3, but not PPRE1 and
PPRE2, in adipocytes in the presence of rosiglitazone.
These results suggest that PPAR could stimulate
GPx3 expression through binding to the mouse GPx3
promoter, and that the activation of PPAR with TZD
could reduce systemic oxidative stress, at least par-
tially, by up-regulating the GPx3 expression in the fat
tissues.
GPx3 Overexpression in Adipocytes Ameliorates
High-Glucose-Induced Inflammatory Gene
Expression and ROS Accumulation, Whereas
GPx3 Neutralization Enhances Inflammatory
Gene Expression
To gain further insights into the roles of GPx3 in adipo-
cytes, we adenovirally overexpressed GPx3 in 3T3-L1
adipocytes and incubated the cells with sodium selenite
because GPx3 is a selenocystein-containing protein (10).
Analysis of the inflammatory gene expression profiles in
the presence or absence of a hyperglycemic challenge
revealed that GPx3 overexpression in 3T3-L1 adipocytes
significantly repressed the high-glucose-induced ex-
pression of proinflammatory genes such as SAA3, resis-
Fig. 3. GPx3 Is Reduced in the Fat Tissue, but not in the Kidney of Obese Mice
A, Northern blot analysis of GPx3 mRNA expression in the kidneys of lean, ob/ob, and db/db mice. B, Northern blot analysis
of GPx3 mRNA expression in the fat tissues of lean, ob/ob, and db/db mice. C, GPx3 mRNA expression was analyzed in the two
fractions (SVCs and adipocytes) obtained by collagenase digestion of adipose tissue from lean and db/db mice. Total RNA
isolated from each fraction was analyzed by quantitative real-time RT-PCR. D, Western blot analyses of GPx3 protein expression
in the fat tissues obtained from lean, ob/ob, and db/db mice. E, GPx activity assays on the total lysates of epididymal fat tissues
from lean and obese mice. F, ROS concentration in the total lysates of fat tissue from lean and obese db/db mice. G, Systemic
oxidative damage as reflected by the TBARS concentrations in the total lysates of fat tissues obtained from lean and obese db/db
mice. The values represent the means  SEM (n  4 or 8). *, P  0.05 for lean mice vs. ob/ob or db/db mice, indicating a significant
difference between the groups. AdipoQ, Adiponectin.
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Fig. 4. Adipose GPx3 Expression Is Suppressed by TNF, LPS, and Hypoxia and Is Stimulated by the Antioxidant NAC
A and B, Adipose GPx3 is suppressed by TNF. 3T3-L1 adipocytes (A) or epididymal fat tissue (B) was incubated with TNF
(10 ng/ml), and the expression of each gene was analyzed by quantitative real-time RT-PCR. , TNF treatment for 8 h. Error bars
indicate the SEM (n  2). C, Northern blot analysis of GPx3 mRNA expression in fat tissues obtained from vehicle- and LPS-treated
lean mice. LPS was administered to lean C57/BL6 mice as an ip injection for 24 h (5 g) or 4 h (50 g). D, GPx activity assays
for total lysates of fat tissues obtained from control and LPS-treated (5 g, 24 h) mice. Error bars indicate the SEM (n  4). E,
Northern blot analysis of GPx3 mRNA expression in kidney from vehicle- and LPS-treated lean mice. LPS was administered to
lean C57/BL6 mice as an ip injection for 24 h (5 g) or 4 h (50 g). F, GPx3 expression in adipocytes is repressed by hypoxia.
3T3-L1 adipocytes were incubated with CoCl2 (100 M) for 24 h. The expression of each gene was analyzed by quantitative
real-time RT-PCR. Error bars indicate the SEM (n  2). G and H, Differential regulation of GPx3 expression in the adipose tissue
(G) and the kidneys (H) by the antioxidant NAC. db/db mice were ip injected with NAC for 1 wk. Expression of each mRNA was
analyzed by quantitative real-time RT-PCR. Error bars indicate the SEM (n  3). *, P  0.05; **, P  0.01 for vehicle- vs. drug-treated
group, indicating a significant difference between the groups. AdipoQ, Adiponectin; Ctl, control.
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tin, and CCR2 (18, 49) (Fig. 6). Additionally, it suppressed
the expression of the p47 and p67 subunits of the
NADPH-oxidase complex (Fig. 6), which are regulated by
nuclear factor-B and TNF (50). More interestingly,
ROS released from the adipocytes into the medium were
reduced by GPx3 overexpression under high glucose
conditions (Fig. 7A). Because ROS has been reported to
trigger insulin resistance in adipocytes (17, 18), we ex-
amined the effects of GPx3 overexpression on high-
glucose-induced insulin resistance. Incubation of 3T3-L1
adipocytes in high-glucose media substantially reduced
the insulin-stimulated glucose uptake (by 33%) (18),
whereas GPx3 overexpression in 3T3-L1 adipocytes re-
stored the insulin-stimulated glucose uptake under the
same conditions (Fig. 7, B and C).
To confirm the effects of adipose GPx3 on inflam-
matory gene expression, we tried to perform loss-of-
function experiments in adipocytes. Because 3T3-L1
adipocytes expressed extremely low levels of GPx3
compared with primary adipocytes, we failed to obtain
substantial knockdown of GPx3 expression via siRNA.
Alternatively, we adopted antibody-assisted neutral-
ization with primary mouse adipocytes. As illustrated
in Fig. 8A, treatment of GPx3-specific antibodies to
neutralize secreted GPx3 from adipocytes promoted
the expression of several inflammatory genes. Of in-
Fig. 5. GPx3 Is Regulated by Rosiglitazone and PPAR
A, GPx3 expression in adipocytes is induced by rosiglitazone. 3T3-L1 adipocytes were incubated with or without rosiglitazone
for 18 h. The mRNA levels were analyzed by quantitative real-time RT-PCR. Error bars indicate the SEM (n  2). B, Adipose GPx3
expression is stimulated by rosiglitazone in db/db mice. db/db Mice were administered an oral gavage of rosiglitazone (5 mg/kg)
for 10 d. Total RNA was prepared from the epididymal fat tissues and was subjected to real-time RT-PCR analysis. Error bars
indicate the SEM (n  4). **, P  0.01. C, Systemic oxidative damage as reflected by the TBARS concentrations in the serum
samples obtained from normal and db/db mice. The values represent the means  SEM (n  4). *, P  0.05. D, Schematic
presentation of putative PPRE motifs in the mouse GPx3 promoter region. E, Gel shift assays were performed with 32P-labeled
ARE7 oligonucleotide containing an endogenous PPRE on the enhancer region of mouse aP2 gene as a probe and in vitro
translated PPAR and RXR proteins. The specific probe-PPAR/RXR complex was abolished by addition of 100-fold molar
excess of unlabeled ARE7 (lane 8) and the three putative PPRE motifs (lanes 3–5), but not E-box (lane 7) and PPRE3-mutant. In
competitors, 3, PPRE3; 2, PPRE2; 1, PPRE1; 3m, PPRE3 mutant; NS, nonspecific competitor (E-box); SC, specific competitor
(ARE7). F, ChIP analysis of GPx3 promoter. 3T3-L1 preadipocytes or fully differentiated adipocytes were incubated with or without
rosiglitazone (10 M) for 48 h. For each experiment, 0.5% of input was used. IgG, Purified nonspecifc IgG; PPAR, anti-PPAR
antibody; AdipoQ, adiponectin; Rosi, rosiglitazone; Veh, vehicle.
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terest, the level of GPx3 protein in the adipocyte-
conditioned media was comparable to that observed
in plasma of lean B6 mice, suggesting that GPx3 con-
centration might be enough to mediate antioxidative
properties (Fig. 8B). Taken together, these results
strongly indicate that GPx3 overexpression in adipo-
cytes would alleviate the proinflammatory gene expres-
sion and oxidative burst induced by hyperglycemia and
ameliorate high-glucose-induced insulin resistance.
DISCUSSION
Accumulating evidence indicates that expanding
stressful conditions in the adipose tissue of obesity,
including hypoxia and macrophage infiltration, could
induce local inflammation and ROS accumulation to
affect dysregulation of adipocytokine genes and sys-
temic oxidative stress, resulting in metabolic abnor-
malities. Recently, it has been also shown that oxida-
tive stress increases selectively in the adipose tissue
of obesity, which confers systemic oxidative stress to
raise risks for obesity-related metabolic complications
(5). As plausible candidates fetching oxidative stress in
the adipose tissue of obesity, we and others reported
that the activities of the NADPH oxidase and a
NADPH-producing enzyme, glucose-6 phosphate de-
hydrogenase, are elevated in the fat tissues of obese
mice, and they trigger local ROS accumulation and
inflammation in adipose tissue (5, 51, 52). However,
the molecular mechanism by which a local increase in
oxidative stress in the fat tissues could bring about a
systemic increase in the ROS accumulation in obesity
remains unclear.
In this study, we demonstrated that the prooxidative
conditions such as hypoxia and inflammation could
reduce adipose GPx3 expression and, thereby, con-
tribute to the decreased plasma GPx activity. As a
major antioxidant enzyme in circulation, reduced
plasma GPx3 level has been shown to be associated
with enhanced systemic oxidative stress to increase
susceptibility to childhood idiopathic stroke (53, 54),
Fig. 6. Adenoviral Overexpression of GPx3 in Adipocytes Reduces Proinflammatory Gene Expression in Adipocytes
3T3-L1 adipocytes were infected with a green fluorescent protein (GFP)- or GPx3-expressing adenovirus (multiplicity of
infection  50). Two days after infection (80% of cells were GFP positive), the cells were incubated with low (5.5 mM)- or high
(25 mM)-glucose DMEM for additional 24 h. The medium was supplemented with sodium selenite (0.1 M) throughout the
experiments. The mRNA levels of proinflammatory genes were analyzed by quantitative real-time RT-PCR. SEM are indicated by
the error bars (n  2). **, P  0.01. Ad-GFP, Adenoviral GFP.
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suggesting that extracellular GPx activity is critical for
maintaining plasma oxidative tone and normal vascu-
lar function. Therefore, it seems that down-regulation
of adipose GPx3 expression and subsequent de-
crease in circulating GPx activity might be associated
with the obesity-related rise in systemic oxidative
stress and incidence of metabolic complications.
Because excessive levels of ROS play causative
roles in the development of insulin resistance and di-
abetes (55, 56), it has been speculated that increased
GPx activity could have beneficial effects on glucose
metabolism. However, GPx1-overexpressing trans-
genic mice develop insulin resistance along with ham-
pered insulin function, probably due to overquenching
of the intracellular ROS burst required for insulin sen-
sitization (57). An acute intracellular ROS burst after
insulin stimulation is required for sensitizing insulin
signaling to suppress protein tyrosine phosphatase
activity (58). Thus, it appears that reducing the ROS
accumulation in circulation while maintaining proper
intracellular ROS tone may be critical for managing
glucose homeostasis in diabetic subjects. In this re-
gard, we highlight the use of GPx3 as a potential target
for intervention in insulin resistance. GPx3 functions as
a major extracellular antioxidant enzyme, and its over-
expression in adipocytes was observed to reduce
ROS accumulation, diminish proinflammatory gene
expression, and ameliorate hyperglycemia-induced in-
sulin resistance (Figs. 6 and 7). Additionally, we ob-
served that glucose tolerance was improved in db/db
mice by administering the antioxidant NAC (data not
shown), suggesting that increased systemic antioxida-
tive activity may reverse obesity-related glucose intol-
erance. Therefore, it is likely that GPx3 would partici-
pate in controlling ROS-induced stress in circulation
as well as in adipose tissue, thus modulating the en-
ergy homeostasis of the whole body, and that it would
play a protective role in obesity-related metabolic
disorders
Interestingly, we observed that circulating GPx3 lev-
els closely correlated with adipose GPx3 expression
rather than that in the kidneys of obese animals (Figs.
1 and 3) (supplemental Figs. 1 and 2). GPx3 is ex-
pressed most abundantly in the kidneys (Fig. 2). Fur-
ther, anephric individuals show reduced plasma GPx
activity and GPx3 protein expression, which is re-
versed by kidney transplantation (59–61). Thus, it had
been suspected that circulating GPx3 appears to be
derived mainly from the kidneys. However, to our sur-
prise, kidney GPx3 expression was not altered or even
slightly increased when circulating GPx3 expression
was substantially reduced in obese ob/ob and db/db
mice (Figs. 1 and 3). With these findings, it would be
feasible to propose that reduced circulating GPx ac-
tivity in obese animals would be primarily correlated
with decreased adipose GPx3 expression. However, it
remains to be elucidated whether kidney GPx3 ex-
pression might also affect reduced plasma GPx3 in
obesity with decreased secretion of GPx3 proteins.
In obesity, adipose tissue gradually develops hyp-
oxia due to rapid growth in the overall fat cell size and
fat mass. Recently, it has been shown that hypoxia
potently enhances GPx3 expression in Caki-2 renal
cells, and this expression is blocked by treatment with
the antioxidant molecule NAC (62). Because hypoxia
stimulates ROS production, it has been proposed that
increased GPx3 expression may induce an adaptive
response mechanism to oxidative stress under hy-
poxic conditions in the kidneys. However, in the cur-
rent study, we observed that GPx3 expression evi-
Fig. 7. GPx3 Overexpression Reduces ROS Accumulation
and Improves High-Glucose-Induced Insulin Resistance in
3T3-L1 Adipocytes
3T3-L1 adipocytes were infected with a green fluorescent
protein (GFP)- or GPx3-expressing adenovirus (multiplicity of
infection  50). Two days after infection (80% of cells were
GFP positive), the cells were incubated with low- (5.5 mM) or
high-glucose (25 mM) DMEM. The medium was supple-
mented with sodium selenite (0.1 M) throughout the exper-
iments. A, The level of ROS released from the adipocytes was
measured using the Amplex Red hydrogen peroxide assay
kit, as described in Materials and Methods. **, P  0.01. B,
Glucose uptake assays. Twenty-four hours after incubation in
low- or high-glucose media, the cells were incubated in the
presence or absence of insulin for 1 h; [14C]2-deoxy-glucose
was added for 30 min and its uptake was measured. The
values represent the means  SEM (n  3). *, P  0.05. C,
Insulin-stimulated glucose uptake activity. The relative activ-
ities were determined by normalizing the values in panel B in
the presence of insulin with the values obtained in the ab-
sence of insulin. Ad-GFP, adenoviral GFP; Ad-GPx3, adeno-
viral GPx3.
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dently decreased in the adipose tissue but increased
slightly in the kidneys of obese animals such as ob/ob
and db/db mice (Fig. 3) (supplemental Fig. 1). Addi-
tionally, GPx3 expression was specifically diminished
in the adipocytes but remained unaltered in the SVCs
of the fat tissues in obese mice (Fig. 3C). Moreover, the
GPx3 expression in adipocytes was reduced in CoCl2-
induced hypoxic conditions (Fig. 4F), indicating that
cell type-specific regulation of GPx3 in adipocytes due
to hypoxia could be at least partly responsible for the
down-regulation of GPx3 mRNA in the adipose tissue
of obese mice.
Another potential mechanism responsible for re-
duced GPx3 expression in the adipocytes of obese
mice is related to chronically augmented local inflam-
mation with increased macrophage infiltration into the
adipose tissue. We observed that the adipose GPx3
mRNA level was diminished by inflammatory signals of
TNF and LPS in vitro and in vivo (Fig. 4). TNF in-
creases the ROS generation in adipose tissue by stim-
ulating iNOS expression and the NADPH oxidase ac-
tivity in adipocytes and macrophages (63, 64). Thus, it
would be plausible that adipose GPx3 expression is
reduced by prooxidative conditions such as inflamma-
tion and hypoxia, which may induce further ROS ac-
cumulation in the adipose tissue and serum of obese
animals. Consistent with this hypothesis, administra-
tion of the antioxidant molecule NAC to db/db mice
increased adipose GPx3 expression (Fig. 4G).
TZDs are prominent antidiabetic drugs that are
widely used for decreasing the fasting glucose levels
and improving insulin resistance (43, 44). Additionally,
recent evidence indicates that TZDs also exert protec-
tive effects against cardiovascular diseases, including
atherosclerosis, thrombosis, and stroke, due to their
antiinflammatory and antioxidative properties (42). Of
the TZDs, troglitazone reduces ROS accumulation by
directly scavenging superoxide anions (65, 66). More-
over, pioglitazone and rosiglitazone reduce systemic
oxidative stress in diet-induced obese mice by un-
known mechanisms in the absence of direct ROS
scavenging (65). Here, we demonstrated that rosigli-
tazone can reduce systemic ROS accumulation by
inducing GPx3 expression via the stimulation of
PPAR in adipose tissue (Fig. 5). It is interesting to
note that adipose GPx3 expression was suppressed
under stressful conditions such as inflammation and
hypoxia (Fig. 4), wherein PPAR expression is sub-
stantially reduced in adipocytes (37, 67). Moreover,
GPx3 down-regulation in obese subjects was shown
to be restricted to the adipocytes where PPAR is
dominantly expressed, but not in SVCs. These results
imply that PPAR is one of the major transcriptional
regulators of GPx3 expression, at least in adipocytes,
and explain why GPx3 was decreased most severely and
selectively in the adipose tissue of obese subjects.
In summary, we have provided the first evidence
that defective GPx3 expression in adipose tissue is
associated with reduced systemic GPx activity and
increased oxidative stress in obesity. Furthermore, we
demonstrated that hypoxia and TNF regulate GPx3 in
a tissue-specific manner that is possibly regulated by
PPAR; this may induce obesity-related down-regulation
of adipose GPx3 expression, leading to augmented
systemic oxidative stress and the onset of metabolic
complications such as diabetes and cardiovascular
diseases. In this respect, it is possible to propose that
local ROS accumulation in the adipose tissue of obe-
sity could be expanded into systemic oxidative stress
by the vicious cycle wherein increasing local ROS
Fig. 8. Neutralization of GPx3 with Anti-GPx3 Antibodies Stimulates Proinflammatory Gene Expression in Mouse Primary
Adipocytes
A, Mouse primary adipocytes were obtained by collagenase digestion of adipose tissue from lean C57/BL6 mice. Cells were
incubated with a rabbit control IgG (mock) or purified anti-GPx3 antibodies (IgG fraction) for 24 h. Total RNA isolated from each
group was analyzed by quantitative real-time RT-PCR. B, GPx3 protein concentration in each sample was assessed by using a
GPx3 ELISA kit.
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accumulation suppresses adipose GPx3 expression.
Thus, these results support further exploration of GPx3




3T3-L1 preadipocytes were grown to confluence in DMEM
supplemented with 10% bovine calf serum. At 2 d postcon-
fluence, the 3T3-L1 cells were incubated for 48 h with DMEM
containing 10% fetal bovine serum, methylisobutylxanthine
(500 M), dexamethasone (1 M), and insulin (5 g/ml). Every
alternate day, the culture medium was replaced with DMEM
containing 10% fetal bovine serum and insulin (1 g/ml).
Adipose Tissue Culture
Mouse epididymal adipose tissue was evenly minced and
incubated in DMEM with 0.1% BSA and antibiotics (penicillin
and streptomycin), in the presence or absence of 10 ng/ml
recombinant murine TNF for 8 h.
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR was performed as previ-
ously described (68). rRNA (18S) was used as the invariant
control. The primers used were as follows: GPx3-forward (f),
5-TAATTTCCAGCTCTTTGAGAAA-3; GPx3-reverse (r), 5-GG
AACTTCTCAAAGTTCCAGCG-3; iNOS-f, 5-AATCTTGGGC-
GAGTTGTGG-3; iNOS-r, 5-CAGGAAGTAGGTGAGGGCTTG-3;







GTTGCAAGCTCTC-3; and adiponectin-r, 5-GTTGGTAT-
CATGGAAGAGAAG-3.
GPx Activity Assay
GPx activity was measured according to the manufacturer’s
protocol (Northwest Life Science Specialties, Vancouver, WA).
Lipid Peroxidation (LPO) and H2O2 Concentration
The tissue samples were homogenized and centrifuged, and
the supernatant was used for the subsequent assays. The
levels of LPO in the plasma and tissue homogenate were
measured in terms of TBARS by performing the LPO test
(Oxford Biomedical Research, Rochester Hills, MI). The H2O2
concentration was measured using an Amplex Red hydrogen
peroxide assay kit (Invitrogen, Carlsbad, CA).
Gel Shift Assay
Gel shift assays were performed as described previously (69).
One microgram of plasmid DNA expressing PPAR or RXR
was used as template for in vitro translation. The DNA se-
quences of the double-stranded oligonucleotides used as
probe or competitors were as follows (only one strand is
shown): ARE7, 5-GATCTGGAACTCTGATCCAGTAAG-3;
PPRE1, 5-GCTGGAGGTTAGAAGTCAACTCT-3; PPRE2, 5-
TAATGGGGTCACAGGTTATGCCA-3; PPRE3, 5-GAATT-
TGAACTTTAACCCGAGG-3; PPRE3-mutant, 5-GAATTA-
AAACTTAAACCCGAGG-3. Probe was end labeled with
[-32P]ATP. Purified probe (30,000 cpm) and proteins were
used in 20 l binding reactions containing reaction buffer [10
mM Tris (pH 7.5), 50 mM KCl, 2.5 mM MgCl2, 0.05 mM EDTA,
0.1% (vol/vol) Triton X-100, 8.5% (vol/vol) glycerol, 1 g of
polydeoxyinosinic deoxycytidylic acid, 1 mM dithiothreitol,
and 0.1% (wt/vol) nonfat dry milk]. Samples were loaded onto
a nondenaturing 4% polyacrylamide gel. The gels were dried
and autoradiographed.
ChIP Analysis
ChIP assays were performed as described previously (68).
Primers used were as follows: PPRE1-f, 5-CAGCTAGT-
CACATGCCTCCA-3; PPRE1-r, 5-TCAGCAGGTAAAA-
GCCCTCA-3; PPRE2-f, 5-CCTGCCATTTATGTGGTGCT-




All experiments were approved by the Seoul National Univer-
sity Animal Experiment Ethics Committee. Male C57BL/6J,
ob/ob, and db/db mice were housed in colony cages under
12-h light, 12-h dark cycles. For rosiglitazone treatment, the
mice received an oral gavage of the drug (5 mg/kg body
weight) (Calbiochem, La Jolla, CA) daily for 10 d. After the
final administration, the animals were fasted for 4 h, and the
plasma glucose levels were tested to confirm the hypoglyce-
mic effects (glucose level 200 mg/dl) of rosiglitazone. The
animals were killed by cervical dislocation 1 d later. For LPS
injection, the mice were ip injected with the vehicle (PBS) or
with 5 g (for 24 h) or 50 g (for 4 h) LPS.
Human Serum Samples
Human serum samples provided by Samsung Medical Center
were analyzed for GPx3 protein expression and GPx activity.
The procedure for obtaining human serum samples was ap-
proved by the Samsung Medical Center Institutional Review
Board (IRB file no. 2006-03-053), and written informed con-
sent was obtained from the volunteers.
Measurement of Glucose Uptake
Insulin-stimulated glucose uptake in the 3T3-L1 adipocytes
was determined by measuring the [14C]2-deoxyglucose up-
take as described previously (51). In short, adenovirus-in-
fected 3T3-L1 adipocytes were incubated in low- (5.5 mM) or
high-glucose (25 mM) DMEM containing 0.1% BSA for 24 h at
37 C. The cells were stimulated with 100 nM insulin for 1 h at
37 C or were left untreated. Glucose uptake was initiated by
treatment with [14C]2-deoxy-d-glucose at a final concentra-
tion of 3 mol/liter in HEPES-buffered saline [140 mM NaCl, 5
mM KCl, 2.5 mM MgCl2, 1 mM CaCl2, and 20 mM HEPES (pH
7.4)] for 10 min. The reaction was terminated by separating
the cells from the HEPES-buffered saline and [14C]2-deoxy-
d-glucose. After three washings in ice-cold PBS, the cells
were extracted with 0.1% sodium dodecyl sulfate and sub-
jected to scintillation counting to determine their 14C radio-
activity. The protein concentrations were determined using a
bicinchoninic acid assay kit (Pierce Chemical Co., Rockford,
IL), and the radioactivities were normalized by determining
each protein concentration.
GPx3 Neutralization
Mouse primary adipocytes were prepared by collagen diges-
tion. After washing three times with DMEM supplemented
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with 0.2% BSA, cells were treated with either the IgG
fraction of a polyclonal rabbit antibody to mouse GPx3 (1
g/ml) or with equivalent mounts of normal rabbit IgG as a
control for 24 h.
Measurement of GPx3 Concentration
GPx3 protein concentration was measured using ELISA ac-
cording to the manufacturer’s protocol (Adipogen, Seoul,
Korea).
Statistical Analysis
All the results are presented as mean  SEM. Statistical sig-
nificance was assessed by Student’s t test. Differences were
considered statistically significant at P  0.05.
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